Table 2.
Summary of published trials with ferric citrate
| Author/journal year | Study phase | Subjects enrolled | Comparator | Duration | Main results |
|---|---|---|---|---|---|
| Yokoyama K Am J Nephrol 2012 [21] |
Dose-response | 192 | Placebo | 28 days | Pi decrease is dose dependent up to 6 g/day Pi decreased −2.16 with 3 g/day; Pi < 5.5 in 50% with 3 g/day |
| Dwyer JP Am J Kid Dis 2013 [22] |
Dose-response | 151 | None | 28 days | FC 6 g/day decrease Pi −1.9 ± 1.7 mg/dL and 8 g/day, −2.1 ± 2.0 mg/dL |
| Yokoyama K Nephrol Dial Transp 2014 [23] |
III | 230 | Sevelamer HC 3–9 g/day |
12 weeks | Pi −0.82 mmol/L with FC and −0.78 with sevelamer (non-inferiority) with sig. increase in ferritin and transferrin sat |
| Lee CT Nephrol 2014 [24] |
III | 166 | Placebo | 8 weeks | Pi decrease with 4 and 6 g/day; increase in ferritin and transferrin sat |
| Lewis JB JASN 2014 [25] |
III | 441 | Active control and Placebo | 52 weeks | Pi −2.2 mg/dL compared to Placebo and similar to active control but higher mean iron parameters with less IV iron |